Congratulations to Dr Vijesh Vaghjiani, Postdoctoral Scientist in the Developmental and Cancer Biology Research group who has been awarded one of two Sarcoma Research Grants by Australia and New Zealand Sarcoma Association (ANZSA).
Dr Vaghjiani’s research aims to target oncogenic drivers in therapy-resistant osteosarcoma – a highly aggressive tumour of the bone, primarily affecting children, adolescents, and young adults.
Targeting oncogenic drivers in therapy-resistant osteosarcoma
Dr Vijesh Vaghjiani
Osteosarcoma survival rates have not improved significantly since the introduction of chemotherapy 40 years ago, highlighting the urgent need for better understanding of tumour biology and new and improved prognostic and therapeutic strategies, especially for patients with metastatic and recurrent disease. Using cutting-edge technologies, Dr Vijesh Vaghjiani will investigate the underlying causes that lead to the development of recurrent disease.
The outcomes from this project will provide insights into the patients likely to develop recurrent disease due to poor response to standard of care chemotherapy and provide and path for future investigation of novel treatments. This project has enormous potential to greatly improve the clinical care and outcomes of osteosarcoma patients.
Contact us
Hudson Institute communications
t: + 61 3 8572 2761
e: communications@hudson.org.au
